By Admin
Scientists are testing an experimental cancer drug designed to exploit a weakness in cancer cells, raising hopes for a new approach to treating the disease, although its safety and effectiveness in humans remain unproven.
The drug, AOH1996, developed by researchers at City of Hope, a US cancer research and treatment organisation, targets a protein known as proliferating cell nuclear antigen (PCNA), which plays a critical role in DNA replication and repair.
By interfering with this process, the drug aims to disrupt cancer cells’ ability to copy their DNA and multiply, potentially slowing or stopping tumour growth.
In laboratory experiments, AOH1996 demonstrated activity against more than 70 types of cancer cells, while causing less harm to the healthy cells tested, according to research published in Cell Chemical Biology in 2023.
The researchers also evaluated the drug in animal studies before advancing it to early human testing.
As of October 2026, AOH1996 remains an experimental drug under Phase 1 clinical investigation. The US National Cancer Institute lists clinical trials examining its use in patients with advanced solid tumours and certain blood cancers.
These early-stage studies are designed primarily to assess the drug’s safety, side effects and appropriate dosage, while also looking for preliminary evidence that it can benefit patients. They are not intended to establish definitive proof of effectiveness.
The research is significant because cancer cells depend on DNA replication to sustain their rapid growth. Targeting the machinery involved in this process could provide a different way to attack tumours, including cancers that respond poorly to existing treatments.
However, promising laboratory findings do not guarantee that a drug will work safely or effectively in people. AOH1996 must undergo further testing to establish whether its potential benefits outweigh its risks and whether it can improve outcomes for cancer patients.
The findings offer a possible new direction in cancer drug development, but AOH1996 is not an approved or established cancer treatment. Its ultimate value will depend on the results of ongoing clinical trials and subsequent research.
The study, led by scientists at City of Hope, was published in Cell Chemical Biology in 2023 under the title “AOH1996: A small molecule targeting cancer-associated proliferating cell nuclear antigen (PCNA).”
